MAI Capital Management Grows Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

MAI Capital Management grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 33.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,539 shares of the biopharmaceutical company’s stock after acquiring an additional 1,871 shares during the period. MAI Capital Management’s holdings in Gilead Sciences were worth $547,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in GILD. FSB Premier Wealth Management Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $28,000. OLD Second National Bank of Aurora lifted its stake in shares of Gilead Sciences by 46.3% in the 3rd quarter. OLD Second National Bank of Aurora now owns 439 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 139 shares during the period. Capital Advisors Ltd. LLC lifted its stake in shares of Gilead Sciences by 127.6% in the 4th quarter. Capital Advisors Ltd. LLC now owns 446 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 250 shares during the period. Dark Forest Capital Management LP acquired a new position in shares of Gilead Sciences in the 3rd quarter valued at $34,000. Finally, Central Bank & Trust Co. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $36,000. 80.16% of the stock is currently owned by institutional investors and hedge funds.

Several research firms recently issued reports on GILD. Oppenheimer decreased their target price on shares of Gilead Sciences from $100.00 to $90.00 in a research note on Thursday, February 3rd. Morgan Stanley reduced their price objective on shares of Gilead Sciences from $69.00 to $63.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 12th. Argus upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $75.00 price objective for the company in a research report on Friday, January 28th. Piper Sandler reduced their price objective on shares of Gilead Sciences from $73.00 to $69.00 and set a “neutral” rating for the company in a research report on Monday, May 16th. Finally, Bank of America reduced their price objective on shares of Gilead Sciences from $73.00 to $71.00 and set a “neutral” rating for the company in a research report on Wednesday, February 2nd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Gilead Sciences has an average rating of “Hold” and an average price target of $72.67.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 3,634 shares of the stock in a transaction dated Friday, March 11th. The shares were sold at an average price of $58.24, for a total transaction of $211,644.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Shares of GILD opened at $63.84 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.30 and a debt-to-equity ratio of 1.31. Gilead Sciences, Inc. has a 12-month low of $57.19 and a 12-month high of $74.12. The firm has a 50-day moving average price of $61.08 and a 200 day moving average price of $65.15. The firm has a market capitalization of $80.08 billion, a P/E ratio of 17.83, a P/E/G ratio of 0.45 and a beta of 0.38.

Gilead Sciences (NASDAQ:GILDGet Rating) last announced its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $2.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.35. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.28 billion. Gilead Sciences had a net margin of 16.43% and a return on equity of 44.98%. Gilead Sciences’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.08 earnings per share. Equities research analysts predict that Gilead Sciences, Inc. will post 6.6 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 29th. Shareholders of record on Wednesday, June 15th will be paid a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 4.57%. The ex-dividend date of this dividend is Tuesday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 81.56%.

Gilead Sciences Profile (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Further Reading

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDGet Rating).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.